Hims & Hers Health (NYSE:HIMS) Shares Gap Up to $11.26

Hims & Hers Health, Inc. (NYSE:HIMS) shares gapped up prior to trading on Monday . The stock had previously closed at $11.26, but opened at $11.80. Hims & Hers Health shares last traded at $11.68, with a volume of 3,705,664 shares.

Analyst Ratings Changes

HIMS has been the subject of several research analyst reports. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Guggenheim boosted their price target on Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Piper Sandler raised their price objective on Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Tuesday, February 27th. SVB Leerink started coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They issued a “market perform” rating and a $10.00 price objective for the company. Finally, Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.85.

Hims & Hers Health Stock Performance

The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -106.82 and a beta of 0.97. The stock’s fifty day moving average is $14.01 and its two-hundred day moving average is $10.31.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The firm had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm’s revenue for the quarter was up 47.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) EPS. Sell-side analysts predict that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Oluyemi Okupe sold 8,509 shares of Hims & Hers Health stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $85,345.27. Following the sale, the chief financial officer now directly owns 161,699 shares in the company, valued at $1,621,840.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,080 shares of Hims & Hers Health stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. Insiders sold 736,191 shares of company stock valued at $9,733,700 over the last three months. 31.63% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $86,836,000. Vanguard Group Inc. lifted its position in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Hims & Hers Health by 39.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after acquiring an additional 357,590 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Hims & Hers Health by 38.6% in the third quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company’s stock worth $6,494,000 after acquiring an additional 287,552 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health in the 3rd quarter valued at approximately $1,596,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.